Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 1
Submit an article Journal homepage
183
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Megan Othusa Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACorrespondence[email protected]
View further author information
,
Ian Thomasb Centre of Trials Research, Cardiff University, Cardiff, UKView further author information
,
Xu Wangc Department of Biostatistics, University of Washington, Seattle, WA, USAView further author information
,
Cono Aritib Centre of Trials Research, Cardiff University, Cardiff, UKView further author information
,
Priyanka Mehtad Department of Haematology, The University of Bristol, Bristol, UKView further author information
,
Mia Sydenhamb Centre of Trials Research, Cardiff University, Cardiff, UKView further author information
,
Robert K. Hillse Nuffield Department of Population Health, University of Oxford, Oxford, UKView further author information
,
Alan K. Burnettf Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UKView further author information
,
Sucha Nandg Loyola University Medical Center, Maywood, IL, USAView further author information
,
Sarit Assoulineh Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal, CanadaView further author information
,
Laura C. Michaelisi Department of Medicine, Division of Hematology/Oncology, The Medical College of Wisconsin, Milwaukee, WI, USAView further author information
,
Harry P. Erbaj Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USAView further author information
,
Nigel Russellk School of Medicine, Nottingham University, Nottingham, UKView further author information
,
Kathleen F. Kerrc Department of Biostatistics, University of Washington, Seattle, WA, USAView further author information
,
Roland B. Walterl Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;m Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA;n Department of Epidemiology, University of Washington, Seattle, WA, USA;o Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USAView further author information
&
Mike Dennisp Christie Hospital, Manchester, UKView further author information
 show all
Pages 250-252 | Received 10 Jun 2022, Accepted 15 Sep 2022, Published online: 13 Oct 2022

References

  • Short NJ, Konopleva M, Kadia TM, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506–525.
  • Bazinet A, Assouline S. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'. Expert Rev Hematol. 2021;14(2):185–197.
  • Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18(9):577–590.
  • Walter RB, Estey EH. Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: limitations of predictive models. Blood Rev. 2020;44:100679.
  • Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29(4):770–775.
  • Palmieri R, Paterno G, De Bellis E, et al. Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness. Cancers. 2020;12(1):120.
  • Cortes JE, Mehta P. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021;96(4):493–507.
  • Urbino I, Secreto C, Olivi M, et al. Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021. Cancers. 2021;13(20):5075.
  • Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol. 1999;107(1):69–79.
  • Erba HP, Othus M, Walter RB, et al. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American intergroup phase II study SWOG S0432. Leuk Res. 2014;38(3):329–333.
  • Nand S, Othus M, Godwin JE, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013;122(20):3432–3439.
  • Walter RB, Michaelis LC, Othus M, et al. Intergroup LEAP trial (S1612): a randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018;93(2):E49–E52.
  • Steyerberg EW, Harrell FE Jr., Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774–781.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.